Results 21 to 30 of about 129,510 (314)

Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells

Journal of Traditional and Complementary Medicine, 2016
Fagonia arabica (FA) possesses a thrombolytic property which has been earlier reported in our laboratory. Current study was undertaken to investigate the effect of aqueous extract of FA on thrombin-induced tissue plasminogen activator (t-PA) and ...
Prutha D. Aloni, Amit R. Nayak, Sweta R. Chaurasia, Jayant Y. Deopujari, Chhaya Chourasia, Hemant J. Purohit, Girdhar M. Taori, Hatim F. Daginawala, Rajpal S. Kashyap   +8 more
doaj   +1 more source

Role of Tissue-Type Plasminogen Activator in Ischemic Stroke

Journal of Pharmacological Sciences, 2010
Tissue-type plasminogen activator (t-PA) administration has been approved for treating acute ischemic stroke, but delayed treatment is associated with increased risk of cerebral hemorrhage and brain injury. t-PA, a serine proteinase, converts plasminogen
Yasuhiro Suzuki
doaj   +1 more source

The Ly49E receptor inhibits the immune control of acute Trypanosoma cruzi infection [PDF]

, 2016
The protozoan parasite Trypanosoma cruzi circulates in the blood upon infection and invades various cells. Parasites intensively multiply during the acute phase of infection and persist lifelong at low levels in tissues and blood during the chronic phase.
Almeida, Andrade, Antunez, Aune, Avilan, Bern, Cardillo, Carlier, Carnaud, Cesari, Collins, Culbertson, Dowling, Duthie, Duthie, Duthie, Filtjens, Fraser, Frosch, Gritz, Hanke, Keating, Lieke, Lieke, Mekkawy, Meyer Zum Buschenfelde, Mondino, Nagata, Nogueira, Pettengill, Pinazo, Rassi, Robertson, Rottenberg, Santana, Sardinha, Stevenaert, Taveirne, Torrico, Truyens, Truyens, Truyens, Une, Van Beneden, Van Beneden, Van Den Broeck, Van Den Broeck, Vassalli, Wen   +48 more
core   +2 more sources

Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival

Life, 2023
(1) Background: Cancer treatment, including chemotherapy, endocrine therapy, targeted therapy and radiotherapy, has been identified as an important independent risk factor for venous thromboembolism in cancer patients.
Katarzyna Wrzeszcz, Piotr Rhone, Katarzyna Kwiatkowska, Barbara Ruszkowska-Ciastek   +3 more
doaj   +1 more source

Sex Differences in rt-PA Utilization at Hospitals Treating Stroke: The National Inpatient Sample. [PDF]

, 2017
BACKGROUND AND PURPOSE: Sex and race disparities in recombinant tissue plasminogen activator (rt-PA) use have been reported. We sought to explore sex and race differences in the utilization of rt-PA at primary stroke centers (PSCs) compared to non-PSCs ...
Albright, Karen C, Boehme, Amelia K., Branas, Charles C., Carr, Brendan G., Elkind, Mitchell S V S.V., Kallan, Michael J., Kasner, Scott Eric, Mullen, Michael T.   +7 more
core   +2 more sources

Improving the solubility, activity, and stability of reteplase using in silico design of new variants

Research in Pharmaceutical Sciences, 2019
Reteplase (recombinant plasminogen activator, r-PA) is a thrombolytic agent recombined from tissue-type plasminogen activator (t-PA), which has several prominent features such as strong thrombolytic ability and E. coli expressibility.
Hooria Seyedhosseini Ghaheh, Mohamad Reza Ganjalikhany, Parichehreh Yaghmaei, Morteza Pourfarzam, Hamid Mir Mohammad Sadeghi   +4 more
doaj   +1 more source

Novel Situations of Endothelial Injury in Stroke — Mechanisms of Stroke and Strategy of Drug Development: Intracranial Bleeding Associated With the Treatment of Ischemic Stroke: Thrombolytic Treatment of Ischemia-Affected Endothelial Cells With Tissue-Type Plasminogen Activator

Journal of Pharmacological Sciences, 2011
.: Previous studies have shown that the risk of intracranial hemorrhage (ICH) associated with the treatment of ischemic stroke is mainly attributable to antithrombotic agents. On the basis of clinical trials, only tissue-type plasminogen activator (t-PA)
Yasuhiro Suzuki, Nobuo Nagai, Kazuo Umemura   +2 more
doaj   +1 more source

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface [PDF]

The Ukrainian Biochemical Journal, 2019
Platelets play a key role in hemostasis as cofactors of thrombin generation, fibrin polymerization centers­, and initiators of clot retraction, while their ability to modulate clot dissolution remains less understood.
T. Grinenko, О. Yusova, O. Revka, I. Patalakh, T. Yatsenko   +4 more
doaj   +1 more source

Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87) [PDF]

, 2001
Urokinase-type plasminogen activator (uPA) represents a central molecule in pericellular proteolysis and is implicated in a variety of physiological and pathophysiological processes such as tissue remodelling, wound healing, tumor invasion, and ...
Arroyo de Prada, Nuria, Bürgle, Markus, Degitz, Klaus, Kellermann, Josef, Kessler, Horst, Magdolen, Viktor, Riemer, Christoph, Schmiedeberg, Niko, Schmitt, Manfred, Schroeck, Florian, Wilhelm, Olaf G.   +10 more
core   +1 more source

Effect of dsRNA on Mesangial Cell Synthesis of Plasminogen Activator Inhibitor Type 1 and Tissue Plasminogen Activator [PDF]

, 2009
Background/Aims: Viral infections are a major problem worldwide and many of them are complicated by virally induced glomerulonephritides. Progression of kidney disease to renal failure is mainly attributed to the development of renal fibrosis ...
Merkle, Monika, Ribeiro, Andrea, Roeder, Maximilian, Sauter, Matthias, Wörnle, Markus   +4 more
core   +1 more source